OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
Tim Witney is a Professor of Molecular Imaging and Wellcome Trust Senior Research Fellow at King’s College London’s School of Biomedical Engineering & Imaging Sciences.
His group develops next-generation diagnostics to monitor treatment response and identify therapy resistance in cancer. They use pioneering radionuclide therapies to target the very features that cause refractive disease. He is the Co-Founder and Chief Scientific Officer at Nuclide Therapeutics, President-elect for the European Society for Molecular Imaging, and Editor-in-Chief of npj Imaging.
Tim obtained his PhD in Biochemistry from the University of Cambridge in 2010, where he worked in the laboratory of Prof. Kevin Brindle FRS on dynamic nuclear polarisation as a novel method for detecting tumour response to therapy. In 2010, Tim joined Prof. Eric Aboagye’s group at Imperial as a postdoc, developing novel positron emission tomography radiotracers for cancer imaging, before moving to Stanford University in 2013 to work under Prof. Sanjiv Sam Gambhir for further postdoctoral training. In 2015, he established his group at University College London’s Centre for Advanced Biomedical Imaging, supported by a UCL Excellence Fellowship and a Wellcome Trust and Royal Society Sir Henry Dale Fellowship. He moved to King’s College London in 2018 to take up his current post.
